Madrigal Pharmaceuticals retained earnings (accumulated deficit) for the quarter ending December 31, 2024 were $-1.802B, a 34.86% increase year-over-year.
Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2024 were $-1.802B, a 34.86% increase from 2023.
Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2023 were $-1.336B, a 38.81% increase from 2022.
Madrigal Pharmaceuticals retained earnings (accumulated deficit) for 2022 were $-0.963B, a 44.26% increase from 2021.